The prognostic value of elevated vascular endothelial growth factor in patients with osteosarcoma: A meta-analysis and systemic review

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 5, 2012, Pages 819-825

  Qu, Jin Tao ^a   Wang, Mei ^a   He, Hai Long ^a   Tang, Yu ^a   Ye, Xiao Jian ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Meta analysis; Osteogenic sarcoma; Osteosarcoma; Survival; Vascular endothelial growth factor (VEGF)

Indexed keywords

VASCULOTROPIN; ISOPROTEIN; TUMOR MARKER; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; SURVIVAL RATE; SYSTEMATIC REVIEW; TUMOR LOCALIZATION; ALGORITHM; BONE TUMOR; GENE EXPRESSION REGULATION; GENETICS; META ANALYSIS; METABOLISM; MORTALITY; PREDICTIVE VALUE; PROGNOSIS; SURVIVAL; UPREGULATION;

ALGORITHMS; BONE NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OSTEOSARCOMA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN ISOFORMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84862282656     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1149-7     Document Type: Review

References (24)

1. Abdeen A, Chou AJ, Healey JH et al (2009) Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma. Cancer 115(22):5243-5250
2. Boulytcheva IV, Soloviev YN, Kushlinskii NE, Mahson AN (2010) Expression of molecular markers in the tumor and survival prognosis in osteosarcoma. Bull Exp Biol Med 150(2):237-242
3. Charity RM, Foukas AF, Deshmukh NS, Grimer RJ (2006) Vascular endothelial growth factor expression in osteosarcoma. Clin Orthop Relat Res 448:193-198 (Pubitemid 44324869)
4. Ek ET, Ojaimi J, Kitagawa Y, Choong PF (2006) Does the degree of intratumoural microvessel density and VEGF expression have prognostic significance in osteosarcoma. Oncol Rep 16(1):17-23
5. Ellis LM, Walker RA, Gasparini G (1998) Is determination of angiogenic activity in human tumours clinically useful. Eur J Cancer 34(5):609-618
6. Ferrara N, Davis-Smyth T (1997) The biology of vascular endothelial growth factor. Endocr Rev 18(1):4-25 (Pubitemid 27076453)
7. Handa A, Tokunaga T, Tsuchida T et al (2000) Neuropilin-2 expression affects the increased vascularization and is a prognostic factor in osteosarcoma. Int J Oncol 17(2):291-295
8. Ho QT, Kuo CJ (2007) Vascular endothelial growth factor: biology and therapeutic applications. Int J Biochem Cell Biol 39(7-8): 1349-1357 (Pubitemid 47031045)
9. Jung ST, Moon ES, Seo HY, Kim JS, Kim GJ, Kim YK (2005) Expression and significance of TGF-beta isoform and VEGF in osteosarcoma. Orthopedics 28(8):755-760
10. Kaya M, Wada T, Akatsuka T et al (2000) Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 6(2):572-577 (Pubitemid 30111481)
11. Kaya M, Wada T, Nagoya S, Sasaki M, Matsumura T, Yamashita T (2009) The level of vascular endothelial growth factor as a predictor of a poor prognosis in osteosarcoma. J Bone Joint Surg Br 91(6):784-788
12. Lee YH, Tokunaga T, Oshika Y et al (1999) Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. Eur J Cancer 35(7):1089-1093 (Pubitemid 29339192)
13. Oda Y, Yamamoto H, Tamiya S et al (2006) CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis. Mod Pathol 19(5):738-745
14. Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17(24):2815-2834 (Pubitemid 28562978)
15. Picci P, Mercuri M, Ferrari S et al (2010) Survival in high-grade osteosarcoma: improvement over 21 years at a single institution. Ann Oncol 21(6):1366-1373
16. Pignochino Y, Grignani G, Cavalloni G et al (2009) Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Mol Cancer 8:118
17. Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D (2006) Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem 13(16):1845-1857
18. Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542-2550 (Pubitemid 44917502)
19. Schoenleber SJ, Kurtz DM, Talwalkar JA, Roberts LR, Gores GJ (2009) Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer 100(9):1385-1392
20. Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in metaanalyses. Eur J Epidemiol 25(9):603-605
21. Weidner N (1995) Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 147(1):9-19
22. Xu T, Chen J, Lu Y, Wolff JE (2010) EVects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis. BMC Cancer 10:252
23. Zhan P, Wang J, Lv XJ et al (2009) Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J Thorac Oncol 4(9):1094-1103
24. Zhou Q, Zhu Y, Deng Z, Long H, Zhang S, Chen X (2011) VEGF and EMMPRIN expression correlates with survival of patients with osteosarcoma. Surg Oncol 20(1):13-19